Endoscopic En Bloc Versus Piecemeal Resection of Large Nonpedunculated Colonic Adenomas : A Randomized Comparative Trial.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
12 Dec 2023
Historique:
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 11 12 2023
Statut: aheadofprint

Résumé

Endoscopic resection of adenomas prevents colorectal cancer, but the optimal technique for larger lesions is controversial. Piecemeal endoscopic mucosal resection (EMR) has a low adverse event (AE) rate but a variable recurrence rate necessitating early follow-up. Endoscopic submucosal dissection (ESD) can reduce recurrence but may increase AEs. To compare ESD and EMR for large colonic adenomas. Participant-masked, parallel-group, superiority, randomized controlled trial. (ClinicalTrials.gov: NCT03962868). Multicenter study involving 6 French referral centers from November 2019 to February 2021. Patients with large (≥25 mm) benign colonic lesions referred for resection. The patients were randomly assigned by computer 1:1 (stratification by lesion location and center) to ESD or EMR. The primary end point was 6-month local recurrence (neoplastic tissue on endoscopic assessment and scar biopsy). The secondary end points were technical failure, en bloc R0 resection, and cumulative AEs. In total, 360 patients were randomly assigned to ESD ( Procedures were performed under general anesthesia during hospitalization in accordance with the French health system. Compared with EMR, ESD reduces the 6-month recurrence rate, obviating the need for systematic early follow-up colonoscopy at the cost of more AEs. French Ministry of Health.

Sections du résumé

BACKGROUND UNASSIGNED
Endoscopic resection of adenomas prevents colorectal cancer, but the optimal technique for larger lesions is controversial. Piecemeal endoscopic mucosal resection (EMR) has a low adverse event (AE) rate but a variable recurrence rate necessitating early follow-up. Endoscopic submucosal dissection (ESD) can reduce recurrence but may increase AEs.
OBJECTIVE UNASSIGNED
To compare ESD and EMR for large colonic adenomas.
DESIGN UNASSIGNED
Participant-masked, parallel-group, superiority, randomized controlled trial. (ClinicalTrials.gov: NCT03962868).
SETTING UNASSIGNED
Multicenter study involving 6 French referral centers from November 2019 to February 2021.
PARTICIPANTS UNASSIGNED
Patients with large (≥25 mm) benign colonic lesions referred for resection.
INTERVENTION UNASSIGNED
The patients were randomly assigned by computer 1:1 (stratification by lesion location and center) to ESD or EMR.
MEASUREMENTS UNASSIGNED
The primary end point was 6-month local recurrence (neoplastic tissue on endoscopic assessment and scar biopsy). The secondary end points were technical failure, en bloc R0 resection, and cumulative AEs.
RESULTS UNASSIGNED
In total, 360 patients were randomly assigned to ESD (
LIMITATION UNASSIGNED
Procedures were performed under general anesthesia during hospitalization in accordance with the French health system.
CONCLUSION UNASSIGNED
Compared with EMR, ESD reduces the 6-month recurrence rate, obviating the need for systematic early follow-up colonoscopy at the cost of more AEs.
PRIMARY FUNDING SOURCE UNASSIGNED
French Ministry of Health.

Identifiants

pubmed: 38079634
doi: 10.7326/M23-1812
doi:

Banques de données

ClinicalTrials.gov
['NCT03962868']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jérémie Jacques (J)

Hépato-Gastro-Entérologie, CHU de Limoges, Limoges, France (J.J., R.L., J.A., H.L., M.D.).

Marion Schaefer (M)

Hépato-Gastro-Entérologie, CHRU de Nancy, Nancy, France (M.S., J.-B.C.).

Timothée Wallenhorst (T)

Hépato-Gastro-Entérologie, CHU de Rennes, Rennes, France (T.W.).

Thomas Rösch (T)

Department of Interdisciplinary Endoscopy, University Hospital, Hamburg-Eppendorf, Hamburg, Germany (T.R.).

Vincent Lépilliez (V)

Hépato-Gastro-Entérologie, Hôpital Privé Jean Mermoz, Lyon, France (V.L., S.L.).

Stanislas Chaussade (S)

Hépato-Gastro-Entérologie, Hôpital Cochin, Paris, France (S.C., M.B., A.B.).

Jérôme Rivory (J)

Hépato-Gastro-Entérologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France (J.R., F.R., T.P., M.P.).

Romain Legros (R)

Hépato-Gastro-Entérologie, CHU de Limoges, Limoges, France (J.J., R.L., J.A., H.L., M.D.).

Jean-Baptiste Chevaux (JB)

Hépato-Gastro-Entérologie, CHRU de Nancy, Nancy, France (M.S., J.-B.C.).

Sarah Leblanc (S)

Hépato-Gastro-Entérologie, Hôpital Privé Jean Mermoz, Lyon, France (V.L., S.L.).

Florian Rostain (F)

Hépato-Gastro-Entérologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France (J.R., F.R., T.P., M.P.).

Maximilien Barret (M)

Hépato-Gastro-Entérologie, Hôpital Cochin, Paris, France (S.C., M.B., A.B.).

Jérémie Albouys (J)

Hépato-Gastro-Entérologie, CHU de Limoges, Limoges, France (J.J., R.L., J.A., H.L., M.D.).

Arthur Belle (A)

Hépato-Gastro-Entérologie, Hôpital Cochin, Paris, France (S.C., M.B., A.B.).

Anaïs Labrunie (A)

Centre d'Epidémiologie de Biostatistiques et Méthodologie de la Recherche (CEBIMER), CHU de Limoges, Limoges, France (A.L., P.-M.P., J.M.).

Pierre-Marie Preux (PM)

Centre d'Epidémiologie de Biostatistiques et Méthodologie de la Recherche (CEBIMER), CHU de Limoges, Limoges, France (A.L., P.-M.P., J.M.).

Hugo Lepetit (H)

Hépato-Gastro-Entérologie, CHU de Limoges, Limoges, France (J.J., R.L., J.A., H.L., M.D.).

Martin Dahan (M)

Hépato-Gastro-Entérologie, CHU de Limoges, Limoges, France (J.J., R.L., J.A., H.L., M.D.).

Thierry Ponchon (T)

Hépato-Gastro-Entérologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France (J.R., F.R., T.P., M.P.).

Sabrina Crépin (S)

Service de Pharmacologie-Toxicologie et Pharmacovigilfance-Unité de Vigilance des Essais Cliniques, CHU de Limoges, Limoges, France (S.C.).

Loïc Marais (L)

Direction de la Recherche et de l'Innovation, CHU de Limoges, Limoges, France (L.M.).

Julien Magne (J)

Centre d'Epidémiologie de Biostatistiques et Méthodologie de la Recherche (CEBIMER), CHU de Limoges, Limoges, France (A.L., P.-M.P., J.M.).

Mathieu Pioche (M)

Hépato-Gastro-Entérologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France (J.R., F.R., T.P., M.P.).

Classifications MeSH